Last reviewed 2026-05-22 · How we verify

Perazolin (SOBUZOXANE)

Phase 2 active Small molecule ✓ Verified May 2026

Perazolin (generic name: SOBUZOXANE) is a sobuzoxane drug. It is currently in Phase 2 development.

Perazolin works by interacting with specific biological pathways, although the exact details of its mechanism are unclear.

Perazolin is a small molecule with synonyms SOBUZOXANE and SOBUZOXANO. Its exact mechanism and clinical uses are not specified in the provided information.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	SOBUZOXANE
Drug class	sobuzoxane
Modality	Small molecule
Therapeutic area	Other
Phase	Phase 2

Mechanism of action

Imagine your body's cells are like a complex network of roads. Perazolin is like a traffic controller that helps regulate the flow of information and materials between cells. By doing so, it may help to restore balance and normal function in the body, but the exact way it does this is still a mystery.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Perazolin CI brief — competitive landscape report
Perazolin updates RSS · CI watch RSS

Frequently asked questions about Perazolin

What is Perazolin?

Perazolin (SOBUZOXANE) is a sobuzoxane drug.

How does Perazolin work?

Perazolin works by interacting with specific biological pathways, although the exact details of its mechanism are unclear.

What is the generic name of Perazolin?

SOBUZOXANE is the generic (nonproprietary) name of Perazolin.

What drug class is Perazolin in?

Perazolin belongs to the sobuzoxane class. See all sobuzoxane drugs at /class/sobuzoxane.

What development phase is Perazolin in?

Perazolin is in Phase 2.

Drug class: All sobuzoxane drugs
Therapeutic area: All drugs in Other

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing